Systemic treatment with the ROCK2 inhibitor belumosudil in ocular chronic graft versus host disease.

Cohort studyAmerican journal of ophthalmology· Jul 2026

Systemic treatment with the ROCK2 inhibitor belumosudil in ocular chronic graft versus host disease.

Yibo Wu, Bei Ye, Xiaoyu Lai … Yi Luo

Read paper

CorneaCohort studyTreatmentQ1IF 4.2

Belumosudil was linked to improved eye disease severity in over half of patients with steroid-refractory graft-versus-host disease.

Systemic treatment with the ROCK2 inhibitor belumosudil in ocular chronic graft versus host disease.

Yibo Wu … Yi Luo

American journal of ophthalmology · Jul 2026 · Q1 in Ophthalmology

Purpose

To evaluate the efficacy of oral belumosudil on ocular surface disease in patients with steroid-refractory chronic graft-versus-host disease (SR-cGVHD). median CFS decreased from 4 to 3, tear break-up time increased from 1.00s to 2.00s, and Schirmer's test improved from 1.0 mm to 2.0 mm.

Methods

In this retrospective study, we analyzed patients with SR-cGVHD and ocular involvement (oGVHD) treated with belumosudil (200 mg daily).

Results

eye disease got better for over half of patients treated

More results

Among 78 treated patients, 40 had oGVHD; 28 completed both assessments.

The cohort (median baseline NIH eye score: 2; oGVHD severity score: 9) had high-risk cGVHD features: 50.0% had severe systemic cGVHD and 82.1% had conjunctival fibrosis.

“

Conclusion · 1 of 2

Systemic belumosudil was associated with improvements in ocular surface parameters and symptoms in steroid-refractory oGVHD, with favorable tolerability.

Conclusion · 2 of 2

Ocular improvement was closely linked to systemic response, warranting prospective validation.

Systemic treatment with the ROCK2 inhibitor belumosudil in ocular chronic graft versus host disease.

Systemic treatment with the ROCK2 inhibitor belumosudil in ocular chronic graft versus host disease.

Related papers